GlassScriptPhysician profile
Roberta L Korich
NPI 1053496315
$3,091.96
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,247 · 2022: $832 · 2023: $12.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.36 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $373.62 | 2021-2022 | |
| Novo Nordisk INC | $297.50 | 2021-2022 | |
| Pfizer INC. | $280.99 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.72 | 2021-2022 | |
| Lilly USA, LLC | $226.06 | 2021-2022 | |
| Glaxosmithkline, LLC. | $225.22 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.89 | 2021-2022 | |
| Amgen INC. | $117.88 | 2021-2022 | |
| Amarin Pharma, INC. | $80.76 | 2021 | |
| Paratek Pharmaceuticals, INC. | $79.36 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $78.21 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $75.25 | 2021 | |
| Merck Sharp & Dohme LLC | $54.53 | 2021-2023 | Belsomra |
| Teva Pharmaceuticals USA, INC. | $44.34 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $40.90 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.65 | 2022 | |
| Esperion Therapeutics, INC. | $23.04 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $22.30 | 2021 | |
| Bardy Diagnostics, INC. | $16.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.79 | 2021 | |
| Almatica Pharma LLC | $15.46 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.49 | 2022 | |
| Gilead Sciences, INC. | $13.99 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.50 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.82 | 2021 | |
| Inogen, INC. | $8.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Korich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.